Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Search
Generic filters

Actiphage optimised to detect MAP in humans and to support use as ‘DIVA’

This is the first time Actiphage has been used to detect MAP in a human blood sample and also to identify a live infection in a vaccinated goat.
  • June 1, 2022
  • goats, Human health, Latest, Research
Actiphage use as a DIVA test

Johne’s Disease is a wasting disease of ruminants that is caused by Mycobacterium avium subspecies paratuberculosis or MAP. MAP has also been linked to Crohn’s Disease in humans but the connection is not conclusive.

Actiphage is a test for MAP that can detect live bacteria in a sample of white blood cells or milk. It was originally developed to detect MAP inside the white blood cells of cattle, but as the properties of blood from other species of animals can be quite different, sample preparation needs to be optimised for the host.

In a poster presented at ICP 2022, Professor Cath Rees of the University of Nottingham described experiments conducted to optimise Actiphage for use with blood samples from different host species.

This is the first time Actiphage has been used to detect MAP in a human blood sample and also to identify a live infection in a vaccinated goat, supporting its use as a test to ‘Differentiate Vaccinated from Infected Animals’ (DIVA) test.

Actiphage extracts DNA from viable MAP cells

Work has now been carried out to show that the Actiphage assay is compatible with a range of different methods that can be used to purify white blood cells (described below).

Ficoll density gradients – the traditional method of purifying peripheral blood mononuclear cells (PBMCs) that takes advantage of the density differences between white blood cells and other elements found in the blood sample. Specifically this method recovers lymphocytes and monocytes as the “buffy coat layer” but granulocytes are removed along with the majority of the red blood cells. This method is the most laborious, but has been used to recover white blood cells for Actiphage testing from a wide range of animal species, including a number of exotic species, and also for humans

Differential lysis using Ammonium Chloride-Potassium (ACK) – this method specifically lyses just erythrocytes in whole blood as a result of osmotic stress caused by the uptake of ammonium chloride added to the sample and therefore the sample contains lymphocytes, monocytes and granulocytes. After the red blood cells have been lysed, the intact white cells are collected by centrifugation. This method has now been successfully used for cattle, deer, goat and human blood samples prior to the Actiphage assay.

Differential sedimentation – this method causes the red blood cells to stack together to form large complexes (“rouleaux”) that then rapidly fall to the bottom of the sample, leaving the nucleated white blood cells in the upper layer of the sample which can then be recovered using a pipette. Hetasep has been specifically developed for human blood and is compatible with the Actiphage assay, but this product will not achieve this separation for blood from all animals.

Professor Rees, who is also CSO of PBD Biotech, said “It has now been shown that all these methods can be successfully used for purifying white blood cells for use with the Actiphage assay, but the method chosen will depend on the species being tested. However these results demonstrate the versatility of our test and opens up a number of new applications”

Actiphage extracts DNA from viable cells

Actiphage uses bacteriophage as the lysing agent to extract DNA from viable mycobacterial cells ahead of identification with PCR. The robust nature of the mycobacteria means that physical or chemical lysis methods are inefficient. In contrast, the phage lysis has evolved to be highly efficient and this allows Actiphage to detect very low (less than 10 per 50ml) numbers of cells.

Actiphage detects MAP in human blood for first time

For human blood, Hetasep was found to be the best method to purify PBMCs as it is simpler than Ficoll and good agreement was found for test results for samples prepared using both methods.

Samples were obtained from patients with atypical symptoms that had been referred to a tuberculosis clinic. After samples were screened for the presence of Mycobacterium tuberculosis complex (MTBC) DNA, any negative samples (=5) were then screened for the presence of Mycobacterium avium complex (MAC) organisms by amplifying IS1311.

One sample gave a positive result for IS1311, and further analysis (PCR-REA) confirmed that the organism detected in the blood of this patient was a sheep strain of MAP. This is the first report of successful detection of MAP in human blood using the Actiphage assay.

Professor Rees says “This is a very exciting result, and opens the door for using Actiphage to screen for a range of non-tuberculosis mycobacterial diseases in human patients”

Actiphage detects live MAP in vaccinated goat supporting use as a DIVA test

Blood samples from domestic goats (caprine) were initial tested using the standard Actiphage method (Ficoll) used for cattle. However better results were achieved using the ACK lysis method.

Detection of MAP was attempted using the well characterised P90 and P91 primers which target the IS900 element. Previously we found these to be very effective for detection of MAP in bovine blood samples. However when working with goat blood samples it was noticed that PCR sensitivity was poor, especially using a real-time PCR format.

Comparison with MAP genome sequences found a sequence mismatch at the 3’ end of the P90 primer was common in many of the non-cattle MAP strains. A redesigned P90 was designed to avoid this region and this improved PCR sensitivity for caprine samples

The Actiphage assay was then used to screen caprine blood samples of known ELISA status. 60% of ELISA-positive animals gave a positive Actiphage test result, confirming the infection status of these animals. In a set of animals vaccinated with a sub-unit vaccine, Actiphage detected viable MAP in the blood samples from one animal indicating that this animal was infected despite vaccination.

Professor Rees commented “This study provides evidence that Actiphage can also be used as a DIVA test, allowing us to differentiate between naturally infected and vaccinated animals, which will support the use of vaccines as part of MAP control programs.”

Share:

Related posts

Loading...
Mondana Cook, Chief Operating Officer at PBD Biotech

Mondana Cook joins PBD Biotech to bring human TB diagnostic to market

July 19, 2022
New Chief Operating Officer brings experience of tuberculosis vaccine and precision medicine.
Mondana Cook, Chief Operating Officer at PBD Biotech

Mondana Cook joins PBD Biotech to bring human TB diagnostic to market

July 19, 2022
New Chief Operating Officer brings experience of tuberculosis vaccine and precision medicine.
Global Plan to End TB cost of inaction

Improved diagnostics priority in Global Plan to End TB

July 7, 2022
The Global Plan to End TB is a costed public health plan. It aims to cut deaths by 90% in 8 years. A key recommendation of the report is to universally replace sputum microscopy with rapid molecular diagnostics.
Global Plan to End TB cost of inaction

Improved diagnostics priority in Global Plan to End TB

July 7, 2022
The Global Plan to End TB is a costed public health plan. It aims to cut deaths by 90% in...

Actiphage detects Johne’s disease in vaccinated goat

June 9, 2022
A study presented at ICP 2022 has shown that the blood test Actiphage is able to distinguish between goats that are naturally infected and those vaccinated against Mycobacterium avium subspecies paratuberculosis (MAP), the pathogen that causes Johne’s Disease, supporting the...

Actiphage detects Johne’s disease in vaccinated goat

June 9, 2022
A study presented at ICP 2022 has shown that the blood test Actiphage is able to distinguish between goats that...
bison MAP diagnostic

Actiphage identifies strain of mycobacteria in blood of bison

May 26, 2022
Results presented at ICP (12-16th June) from first study in North American bison, shows capacity of Actiphage to sub-type mycobacteria in blood.
bison MAP diagnostic

Actiphage identifies strain of mycobacteria in blood of bison

May 26, 2022
Results presented at ICP (12-16th June) from first study in North American bison, shows capacity of Actiphage to sub-type mycobacteria...
1 2 … 23 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
Ingenuity Centre,
University of Nottingham,
Innovation Park, Triumph Rd,
Nottingham NG7 2TU,
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

Big shout out to all the amazing dairy farmers, together we can eradicate Johne's Disease and the heartbreak that goes with it. #farm24 #agritech @FarmersGuardian @Morrisons https://t.co/f2A1hVLXlj

Read More
PBD Biotech

RT @Jamesrgurney: I’m officially looking to hire some folks! Interested in working on phage coevolution and phage therapy? Hiring grad stud…

Read More
PBD Biotech

“Good diagnostics and a vaccine could prevent 26.5 million human #tuberculosis cases over 8 years, according to Global Plan to End TB" - Mondana Cook is our new Chief Operating Officer, helping us develop rapid molecular #TB #diagnostic. #EndTB @StopTB

Read More